amantadine has been researched along with benserazide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (69.57) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
| Dinnendahl, V; Gumulka, SW; Peters, HD; Schönhöfer, PS | 1 |
| Barbeau, A; Butterworth, RF; Campanella, G; Yamada, K | 1 |
| Lazarova, MB; Roussinov, KS | 1 |
| Clemens, R | 1 |
| Lapin, IP; Patkina, NA | 1 |
| Fernandez, FC; Lindsley, DF; Ranf, SK; Wyrwicka, W | 1 |
| Przewlocki, R | 1 |
| Birkmayer, W | 1 |
| Lieberman, AN | 1 |
| Gressier, H; Malecot, E; Poignant, JC | 1 |
| Candelise, L; Faglioni, P; Spinnler, H; Vignolo, LA | 1 |
| Masi, G; Megna, GF; Puca, FM; Specchio, LM | 1 |
| Cashin, CH; Sutton, S | 1 |
| van der Zee, HJ; van Nieuwenhuizen, O; Zweije-Hofman, IL | 1 |
| Ando, K | 1 |
| Hagell, P; Odin, P; Vinge, E | 1 |
| Arai, A; Kannari, K; Maeda, T; Matsunaga, M; Shen, H; Suda, T | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
2 review(s) available for amantadine and benserazide
| Article | Year |
|---|---|
[Antiparkinsonian drugs (author's transl)].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Receptors, Dopamine | 1980 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline | 1998 |
2 trial(s) available for amantadine and benserazide
| Article | Year |
|---|---|
Letter: Treatment of Huntington's chorea.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Clinical Trials as Topic; Diazepam; Dihydroxyphenylalanine; Drug Therapy, Combination; Haloperidol; Humans; Huntington Disease; Hydrazines; Reserpine | 1973 |
Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.
Topics: Adolescent; Adult; Amantadine; Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Lipidoses; Psychoses, Substance-Induced; Syndrome | 1982 |
19 other study(ies) available for amantadine and benserazide
| Article | Year |
|---|---|
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Effects of dopaminergic stimulants on cyclic nucleotide levels in mouse brain in vivo.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Benserazide; Brain; Cerebellum; Cyclic AMP; Cyclic GMP; Dopamine; Dose-Response Relationship, Drug; Humans; Isoquinolines; Levodopa; Male; Mice; Nucleotides, Cyclic; Stereotyped Behavior | 1976 |
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Platelets; Carbon Radioisotopes; Depression, Chemical; Dopamine; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H1 Antagonists; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Time Factors; Trihexyphenidyl | 1975 |
On certain effects of dopaminergic agents in pentylenetetrazol convulsions.
Topics: Amantadine; Animals; Benserazide; Dextroamphetamine; Dopamine; Drug Interactions; Haloperidol; Levodopa; Male; Mice; Pentylenetetrazole; Rats; Seizures | 1978 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Reserpine; Stereotaxic Techniques | 1976 |
Effects of catecholaminergic drugs on systems of reward and punishment in experiments on cats.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Benserazide; Catecholamines; Cats; Disulfiram; Electric Stimulation; Electrodes, Implanted; Levodopa; Male; Punishment; Reward | 1976 |
Effects of anti-parkinsonian drugs on the motor activity and EEG of cats with subthalamic lesions.
Topics: Amantadine; Animals; Antiparkinson Agents; Attention; Behavior, Animal; Benserazide; Cats; Cerebral Cortex; Cortical Synchronization; Dextroamphetamine; Diencephalon; Electroencephalography; Functional Laterality; Levodopa; Motor Activity; Neural Pathways; Reticular Formation | 1975 |
The effects of apomorphine and 1,3-dimethyl-5-aminoadamantane (DMAA) on ponto-geniculo-occipital (PGO) waves in cats.
Topics: Amantadine; Animals; Apomorphine; Benserazide; Cats; Dopamine; Electroencephalography; Geniculate Bodies; Memantine; Occipital Lobe; Serotonin | 1975 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Comparative effects of apomorphine, piribedil and other neurotropic agents on central analgesic-induced catatonia in the rat.
Topics: Amantadine; Analgesics, Opioid; Animals; Antiparkinson Agents; Apomorphine; Atropine; Benserazide; Benzyl Compounds; Catatonia; Dextroamphetamine; Dextromoramide; Dihydroxyphenylalanine; Dioxoles; Dose-Response Relationship, Drug; Humans; Male; Morphine; Piperazines; Pyrimidines; Rats; Time Factors; Trihexyphenidyl | 1974 |
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Mental Processes; Parkinson Disease; Psychological Tests | 1974 |
The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
Topics: Amantadine; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Benztropine; Brain Chemistry; Catalepsy; Dextroamphetamine; Dihydroxyphenylalanine; Humans; Hydroxydopamines; Methylphenidate; Methyltyrosines; Rats; Reserpine; Scopolamine | 1973 |
Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Amantadine; Analysis of Variance; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dialysis; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2003 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine Agonists; Food, Formulated; Levodopa; Magnesium; Magnesium Deficiency; Male; Mice; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |